Enalapril Maleate Compounded Oral Suspension

2020 ◽  
pp. 118-120
Author(s):  
Aslam Pathan

On 10 January 2020 Taro Pharmaceuticals U.S.A., Inc. Issues voluntary nationwide recall of Lamotrigine tablets USP, 100 mg, 100 count bottles and on 20 February 2020 Taro Pharmaceuticals U.S.A. Issues voluntary nationwide recall of Phenytoin oral suspension USP, 125 Mg/5 Ml due to possible underdosing or overdosing. The reason for the recall of Lamotrigine was found to have been cross-contaminated with a small amount of another drug substance (Enalapril Maleate) used to manufacture another product at the same facility. The reason for the recall of Phenytoin is that products from these two lots of Phenytoin oral suspension may not re-suspend when shaken, as instructed for administration, which could result in under or overdosing. This recall is being conducted with the knowledge of the FDA.


2020 ◽  
Vol 17 ◽  
Author(s):  
Bhumin K. Pathak ◽  
Meenakshi Raghav ◽  
Arti R. Thakkar ◽  
Bhavin A. Vyas ◽  
Pranav J. Shah

Background: Poor dissolution of Etodolac is one of the major challenges in achieving the desired therapeutic effect in oral therapy. Objective: This study aimed to assess the potential of liquisolid compact technique in increasing the rate of dissolution of Etodolac and thus its bioavailability. Methods: Liquisolid compacts were prepared using PEG 400, Avicel PH-200 and Aerosil 200 as non-volatile liquid, carrier and coating material respectively. Optimisation was carried out by applying a 32 full factorial design using Design expert software 11.0.3.0 to examine the effects of independent variables (load factor and carrier: coating ratio) on dependent variables (angle of repose and % cumulative drug release at 30 min [Q 30 min]).Assessment of bioavailability was based on pharmacokinetic study in rabbits and pharmacodynamics evaluation in rats respectively. Results: The formulation M3 was identified as the optimised formulation based on the better flow (lower angle of repose) and a higher rate of dissolution (Q 30 min >95%). The higher dissolution rate could be due to conversion of Etodolac into an amorphous molecularly dispersed state, availability of larger surface area, enhancement of aqueous solubility and enhanced wetting of drug particles. Studies with DSC, XRD, and SEM verified the transformation of Etodolac from crystalline to amorphous state, a key factor responsible for improving the dissolution rate. Pharmacokinetic profile of M3 was prominent, demonstrating higher absorption of Etodolac in comparison of oral suspension and immediate-release conventional tablets in rabbits. Liquisolid formulation exhibited 27% increment in paw thickness as compared to 57% and 46% increments for oral suspension and immediate-release conventional tablets respectively, after 7 hrs in carrageenan-induced paw model in rats. Conclusion: The results indicated liquisolid compact technique to be a promising strategy to enhance the bioavailability of Etodolac.


Hypertension ◽  
1995 ◽  
Vol 25 (6) ◽  
pp. 1345-1350 ◽  
Author(s):  
Alan H. Gradman ◽  
Karen E. Arcuri ◽  
Allan I. Goldberg ◽  
Leila S. Ikeda ◽  
Edward B. Nelson ◽  
...  

2001 ◽  
Vol 58 (11) ◽  
pp. 1021-1024 ◽  
Author(s):  
Paul J. Dentinger ◽  
Chad F. Swenson ◽  
Nasr H. Anaizi

Sign in / Sign up

Export Citation Format

Share Document